2005
Sex-Related Differences in Stimulated Hypothalamic-Pituitary-Adrenal Axis during Induced Gonadal Suppression
Roca C, Schmidt P, Deuster P, Danaceau M, Altemus M, Putnam K, Chrousos G, Nieman L, Rubinow D. Sex-Related Differences in Stimulated Hypothalamic-Pituitary-Adrenal Axis during Induced Gonadal Suppression. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 4224-4231. PMID: 15886244, DOI: 10.1210/jc.2004-2525.Peer-Reviewed Original ResearchConceptsSex-related differencesGonadal suppressionReproductive steroid levelsHypogonadal conditionsAdrenal axisSteroid levelsCortisol-binding globulin levelsCRH stimulation testSex differencesHPA axis measuresHPA axis responseMain outcome measuresHPA axis activityMiddle-aged menFemale normal volunteersLeuprolide injectionACTH ratioCRH stimulationOutpatient clinicStimulation testLeuprolide acetateTime of testingAdrenal responsivityAxis activityGlobulin levels
2004
HPA axis activation in major depression and response to fluoxetine: a pilot study
Young E, Altemus M, Lopez J, Kocsis J, Schatzberg A, deBattista C, Zubieta J. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology 2004, 29: 1198-1204. PMID: 15219644, DOI: 10.1016/j.psyneuen.2004.02.002.Peer-Reviewed Original ResearchConceptsHPA axis activationMetyrapone challengeOnset of treatmentAxis activationMajor depressionHPA axisHamilton Depression Rating Scale ratingsOpen-label treatmentHPA axis dysregulationAdrenal axis activationPremenopausal womenLabel treatmentACTH levelsHormonal contraceptivesMedical illnessACTH secretionAxis dysregulationNormal womenDepressed patientsFluoxetine respondersDepressed womenNormal subjectsAxis IGreater severityFluoxetine
1999
Open trial of flutamide for treatment of obsessive-compulsive disorder.
Altemus M, Greenberg B, Keuler D, Jacobson K, Murphy D. Open trial of flutamide for treatment of obsessive-compulsive disorder. The Journal Of Clinical Psychiatry 1999, 60: 442-5. PMID: 10453797, DOI: 10.4088/jcp.v60n0704.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAndrogen receptorEstrogen receptorClassical intracellular androgen receptorsOCD symptomsPrimary outcome measureFuture treatment trialsIntracellular androgen receptorHamilton Rating ScaleGonadal steroid hormonesAndrogen receptor antagonistYale-Brown Obsessive Compulsive ScaleEffect of treatmentBeck Anxiety InventoryLack of responseObsessive Compulsive ScaleOpen trialTreatment trialsReceptor antagonistGonadal steroidsOutcome measuresCompetitive antagonistEstrogen activityFlutamideSteroid hormonesNormal CSF oxytocin and NPY levels in OCD
Altemus M, Jacobson K, Debellis M, Kling M, Pigott T, Murphy D, Gold P. Normal CSF oxytocin and NPY levels in OCD. Biological Psychiatry 1999, 45: 931-933. PMID: 10202583, DOI: 10.1016/s0006-3223(98)00263-7.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderNPY levelsCSF levelsOCD patientsCSF oxytocinCentral nervous system neuropeptidesIncreased CSF levelsHealthy normal volunteersControl subjectsNPY regulationNormal volunteersHigher CSFSymptom profilesControl groupPatientsPotential mediatorsNeuropeptidesOxytocinSignificant differencesNPYCSFLevelsPrior findingsAbnormalities
1998
Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients
Greenberg B, Benjamin J, Martin J, Keuler D, Huang S, Altemus M, Murphy D. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology 1998, 140: 434-444. PMID: 9888619, DOI: 10.1007/s002130050787.Peer-Reviewed Original ResearchConceptsFluoxetine-treated patientsObsessive-compulsive disorderUnmedicated patientsAdministration of metergolineSerotonin reuptake inhibitorsUnderlie symptomsUntreated patientsBrain serotoninReuptake inhibitorsSerotonin antagonistsSerotonergic transmissionSingle doseSymptom exacerbationReceptor responsivityTherapeutic effectMetergolinePatientsPlaceboSymptom ratingsSymptomsSuch treatmentSerotoninDisordersPilot resultsDays
1996
Hypervigilance in patients with obsessive‐compulsive disorder
Wiggs C, Martin A, Altemus M, Murphy D. Hypervigilance in patients with obsessive‐compulsive disorder. Anxiety 1996, 2: 123-129. PMID: 9160613, DOI: 10.1002/(sici)1522-7154(1996)2:3<123::aid-anxi3>3.0.co;2-q.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderOCD patientsExplicit memory tasksFeature-specific informationRecognition of wordsExplicit memoryMemory taskPriming taskExplicit measuresNormal performanceUnusual wordsSensitive measureMemoryNormal controlsWordsTaskMeasuresHypervigilanceDisordersRecognitionRecallPrimingAttentionFindingsInformation
1993
Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers
De Bellis M, Geracioti T, Altemus M, Kling M. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biological Psychiatry 1993, 33: 636-641. PMID: 7687151, DOI: 10.1016/0006-3223(93)90103-k.Peer-Reviewed Original ResearchConceptsMedication-free patientsHealthy volunteersFluoxetine treatmentHomovanillic acidMean Hamilton Depression Rating Scale scoreHamilton Depression Rating Scale scoresDepression Rating Scale scoresPmol/CSF monoamine metabolite levelsFluoxetine-treated patientsCerebrospinal fluid levelsMajor depressive disorderMonoamine metabolite levelsRating Scale scoresCerebrospinal fluid monoamineHVA/5-HIAA ratioCSF HVA/5-HIAA ratioDepressive disorderMajor depressionScale scoreFluid levelsPatientsDSM-IIIMetabolite levelsVolunteersCSF somatostatin in obsessive-compulsive disorder
Altemus M, Pigott T, L'Heureux F, Davis C, Rubinow D, Murphy D, Gold P. CSF somatostatin in obsessive-compulsive disorder. American Journal Of Psychiatry 1993, 150: 460-464. PMID: 8094599, DOI: 10.1176/ajp.150.3.460.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderCSF somatostatinDrug-free outpatientsSerotonin reuptake inhibitorsSpectrum of disordersSubstantial cognitive deficitsMeasurement of somatostatinPredominant symptomReuptake inhibitorsSomatostatin activitySomatostatin levelsBrain contentPatient subgroupsClinical symptomatologyNormal subjectsNormal volunteersSomatostatinPatientsNeuropharmacological agentsExperimental animalsCognitive deficitsCentral administrationDisordersFunctional significance
1992
Abnormalities in the Regulation of Vasopressin and Corticotropin Releasing Factor Secretion in Obsessive-Compulsive Disorder
Altemus M, Pigott T, Kalogeras K, Demitrack M, Dubbert B, Murphy D, Gold P. Abnormalities in the Regulation of Vasopressin and Corticotropin Releasing Factor Secretion in Obsessive-Compulsive Disorder. JAMA Psychiatry 1992, 49: 9-20. PMID: 1370198, DOI: 10.1001/archpsyc.1992.01820010009002.Peer-Reviewed Original Research
1989
Neuropsychological correlates of menstrual mood changes.
Altemus M, Wexler B, Boulis N. Neuropsychological correlates of menstrual mood changes. Psychosomatic Medicine 1989, 51: 329-336. PMID: 2734425, DOI: 10.1097/00006842-198905000-00007.Peer-Reviewed Original Research